Past SARS-CoV-2 infection elicits a strong immune response after a single vaccine dose
Chahla, R. E.; Tomas-Grau, R. H.; Cazorla, S. I.; Ploper, D.; Vera Pingitore, E.; Aguilar Lopez, M.; Aznar, P.; Alcorta, M. E.; Velez, E. M. d. M.; Stagnetto, A.; Avila, C. L.; Maldonado Galdeano, C.; Socias, S. B.; Heinze, D.; Navarro, S. A.; Llapur, C.; Costas, D.; Flores, I.; Apfelbaum, G.; Mostoslavsky, R.; Mostoslavsky, G.; Perdigon, G. d. V.; Chehin, R.
Show abstract
We hypothesized that in individuals with previous SARS-CoV-2 infection, the first vaccine dose would work as a booster, eliciting a faster and more intense immune response. We herein describe antibody responses to the first and second doses of Gam-COVID-Vac (SPUTNIK V) vaccine in health personnel of Tucuman, Argentina, with previous COVID-19 and compared it with uninfected personnel. Individuals with anti-SARS-CoV-2 titers at baseline showed significantly higher responses to the first dose than people with no prior history of disease (p <0.0001), with titers higher to those registered after the second dose in the control group, representing a clear secondary antibody response. This suggests that a single dose of SPUTNIK V for people with previous SARS-CoV-2 infection could contribute to a better use of available doses. One-Sentence SummaryFirst vaccine dose in subjects with prior COVID19 elicits a higher antibody response than two doses in uninfected individuals
Matching journals
The top 6 journals account for 50% of the predicted probability mass.
Similar papers in this journal
- Kinetics and persistence of the cellular and humoral immune responses to BNT162b2 mRNA vaccine in SARS-CoV-2-naive and - experienced subjects 96%
- Study on the mucosal and serological immune response to the Novel Coronavirus (SARS-CoV-2) vaccines 96%
- Comparison of the mucosal and systemic antibody responses in Covid-19 recovered patients with one dose of mRNA vaccine and unexposed subjects with three doses of mRNA vaccines 96%
Similar papers in this journal
- Functional and quantitative evaluation of BNT162b2 SARS-CoV-2 vaccine-induced immunity 95%
- A novel simian adenovirus vectored COVID-19 vaccine elicits effective mucosal and systemic immunity in mice by intranasal and intramuscular vaccination regimens 94%
- High resolution linear epitope mapping of the receptor binding domain of SARS-CoV-2 spike protein in COVID-19 mRNA vaccine recipients 93%
Similar papers in this journal
- Retention of Neutralizing response against SARS-CoV-2 Omicron variant in Sputnik V vaccinated individuals 95%
- Neutralization of SARS-CoV-2 variants by rVSV-ΔG-spike-elicited human sera 95%
- The fourth dose of mRNA COVID-19 vaccine following 12 different three-dose regimens: Safety and immunogenicity to Omicron BA.4/BA.5 95%
Similar papers in this journal
- Virological and serological kinetics of SARS-CoV-2 Delta variant vaccine-breakthrough infections: a multi-center cohort study 93%
- Antibody responses to BNT162b2 mRNA COVID-19 vaccine in 2,015 healthcare workers in a single tertiary referral hospital in Japan 93%
- Investigation of Vaccine Breakthrough Infections by Vaccine strategy during the Delta Variant Wave in France 93%
Similar papers in this journal
- Longitudinal Study after Sputnik V Vaccination Shows Durable SARS-CoV-2 Neutralizing Antibodies and Reduced Viral Variant Escape over Time 95%
- A booster dose of an inactivated vaccine increases neutralizing antibodies and T cell responses against SARS-CoV-2 95%
- Tetravalent SARS-CoV-2 S1 Subunit Protein Vaccination Elicits Robust Humoral and Cellular Immune Responses in SIV-Infected Rhesus Macaque Controllers 95%
"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.